Seogsong Jeong, Yun Hwan Oh, Joseph C Ahn, Seulggie Choi, Sun Jae Park, Hye Jun Kim, Gyeongsil Lee, Joung Sik Son, Heejoon Jang, Dong Hyeon Lee, Meng Sha, Lei Chen, Won Kim, Sang Min Park
Clin Mol Hepatol 2024;30(3):487-499. Published online May 7, 2024
Background/Aims To determine the association between evolutionary changes in metabolic dysfunction-associated steatotic liver disease (MASLD) status and the risk of hepatocellular carcinoma (HCC) in a nationwide population-based cohort.
Methods Information on study participants was derived from the Korea National Health Insurance Service database. The study population consisted of 5,080,410 participants who underwent two consecutive biennial health screenings between 2009 and 2012. All participants were followed up until HCC, death, or 31 December 2020. The association of evolutionary changes in MASLD status, as assessed by the fatty liver index and cardiometabolic risk factors, including persistent non-MASLD, resolved MASLD, incident MASLD, and persistent MASLD, with HCC risk was evaluated using multivariable-adjusted Cox proportional hazards regression.
Results Among the 5,080,410 participants with 39,910,331 person-years of follow-up, 4,801 participants developed HCC. The incidence of HCC in participants with resolved, incident, and persistent MASLD was approximately 2.2-, 2.3-, and 4.7-fold higher, respectively, than that in those with persistent non-MASLD among the Korean adult population. When stratifying the participants according to the evolutionary change in MASLD status, persistent (adjusted hazard ratio [aHR], 2.94; 95% confidence interval [CI], 2.68–3.21; P<0.001), incident (aHR, 1.85; 95% CI, 1.63–2.10; P<0.001), and resolved MASLD (aHR, 1.33; 95% CI, 1.18–1.50; P<0.001) had an increased risk of HCC compared to persistent non-MASLD.
Conclusions The evolutionary changes in MASLD were associated with the differential risk of HCC independent of metabolic risk factors and concomitant medications, providing additional information on the risk of HCC stratification in patients with MASLD.
Citations
Citations to this article as recorded by
Incidence of Hepatocellular Carcinoma in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Reconstructed Individual Patient Data Meta-Analysis Ryan Yanzhe Lim, Faith Xin Ning Tan, Glenn Jun Kit Ho, Ethan Kai Jun Tham, Alfred Kow, Guoyue Lv, Zhong-Qi Fan, Nicholas Syn, Masahito Nakano, Wenhao Li, Karn Wijarnpreecha, Jörn M. Schattenberg, Vincent Chen, Ming-Hua Zheng, Pojsakorn Danpanichkul, Hirok Clinical Gastroenterology and Hepatology.2026; 24(5): 1236. CrossRef
Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon Clinical Gastroenterology and Hepatology.2026; 24(6): 1644. CrossRef
Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic Ho Soo Chun, Minjong Lee Clinical and Molecular Hepatology.2026; 32(1): 368. CrossRef
Liver cancer risk stratification using deep learning on nationwide longitudinal health screening data: a retrospective cohort study Yewon Choi, Sungmin Cho, Changdai Gu, Chungho Kim, Bomi Park, Hwiyoung Kim BMC Medical Informatics and Decision Making.2026;[Epub] CrossRef
Coexistence of atrial fibrillation and metabolic dysfunction-associated steatotic liver disease as a high-risk overlap for incident heart failure in older adults Jeongin Lee, Sangwook Cheon, Eun Seok Kang, Jihun Song, Hye Jun Kim, Taeho Kwak, Seokjin Kong, Jin-Hyun Park, Minjeong Kang, Seohui Jang, Yihyun Kim, Jinhyeok Choi, Hwamin Lee, Jaewon Khil, Seogsong Jeong European Journal of Heart Failure.2026; 28(2): 260. CrossRef
Editorial: Residual HCC Risk After Hepatitis C Cure—Can Polygenic Risk Scores Refine Surveillance? Heechul Nam, Sung Won Lee Alimentary Pharmacology & Therapeutics.2026; 63(10): 1427. CrossRef
LPCAT3 deficiency Drives phospholipid remodeling and mitochondrial oxidative dysfunction to accelerate MASH-HCC development Gaoxuan Shao, Chenhao Ye, Chenceng Sun, Jiashu Pan, Lu Lu, Lei Wang, Tao Wu, Zemin Lin, Guang Ji, Hanchen Xu Journal of Advanced Research.2026;[Epub] CrossRef
Noncanonical function of epigenetic reader YTHDF1 inhibits MASLD progression by maintaining peroxisomes and mitochondrial homeostasis Chenyang Mu, Jian Tan, Yuefan Wang, Haozan Yin, Zhihui Dai, Zenghan Wang, Dongyang Ding, Zhichao Zhang, Sijie Wang, Hui Liu, Fu Yang Experimental & Molecular Medicine.2026; 58(4): 1172. CrossRef
Alcohol-driven phenotypic transition in MASLD and risk of liver-related events Seohui Jang, Jihun Song, Eun Seok Kang, Sangwook Cheon, Taeho Kwak, Yihyun Kim, Seokjin Kong, Jinhyeok Choi, Minjeong Kang, Jaewon Khil, Hye Jun Kim, Jeongin Lee, Hwamin Lee, Seogsong Jeong JHEP Reports.2026; 8(7): 101866. CrossRef
Longitudinal changes in fatty liver index, genetic susceptibility, and incident atrial fibrillation Siyang Liu, Houde He, Hualan Chen, Hualin Duan, Ying Sun, Dan Deng, Zihao Gui, Lan Liu, Ningjian Wang, Jie Shen, Heng Wan Clinica Chimica Acta.2026; 589: 121028. CrossRef
Statin Use and Risk of Hepatocellular Carcinoma in Metabolic Dysfunction–Associated Steatotic Liver Disease: A National Retrospective Cohort Study Su Gyeong Kim, Ju Hyun Kang, Sun Jae Park, Jiwon Yu, Seogsong Jeong, Sangwoo Park, Ahryoung Ko, Sang Min Park Cancer Prevention Research.2026; 19(5): 303. CrossRef
Association between steatotic liver disease subtype and thyroid cancer in women: A nationwide population-based cohort study Hyunju Park, Arim Choi, Soo-Kyung Kim, Yong-Wook Cho, Kyungdo Han, Kyung-Soo Kim Frontiers in Endocrinology.2026;[Epub] CrossRef
Dietary quality, perceived health, and psychological status as key risk factors for newly developed metabolic dysfunction–associated steatotic liver disease in a longitudinal study Xuangao Wu, Ting Zhang, Sunmin Park Nutrition.2025; 130: 112604. CrossRef
A Novel Point-of-Care Prediction Model for Steatotic Liver Disease: Expected Role of Mass Screening in the Global Obesity Crisis Jeayeon Park, Goh Eun Chung, Yoosoo Chang, So Eun Kim, Won Sohn, Seungho Ryu, Yunmi Ko, Youngsu Park, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan Yoon, Yoon Jun Kim Gut and Liver.2025; 19(1): 126. CrossRef
Cigarette Smoke Contributes to the Progression of MASLD: From the Molecular Mechanisms to Therapy Jiatong Xu, Yifan Li, Zixuan Feng, Hongping Chen Cells.2025; 14(3): 221. CrossRef
KASL clinical practice guidelines for the management of metabolic dysfunction-associated steatotic liver disease 2025 Won Sohn, Young-Sun Lee, Soon Sun Kim, Jung Hee Kim, Young-Joo Jin, Gi-Ae Kim, Pil Soo Sung, Jeong-Ju Yoo, Young Chang, Eun Joo Lee, Hye Won Lee, Miyoung Choi, Su Jong Yu, Young Kul Jung, Byoung Kuk Jang Clinical and Molecular Hepatology.2025; 31(Suppl): S1. CrossRef
Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023” Jeayeon Park, Su Jong Yu Clinical and Molecular Hepatology.2025; 31(2): 625. CrossRef
Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Hai Xu, Yong Zhou, Huikun Wu Clinical and Molecular Hepatology.2025; 31(2): e125. CrossRef
Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e210. CrossRef
Correspondence to editorial on “Adverse impact of metabolic dysfunction on fibrosis regression following direct-acting antiviral therapy: A multicenter study for chronic hepatitis C” Tom Ryu, Young Chang, Seung Up Kim, Jae Young Jang Clinical and Molecular Hepatology.2025; 31(2): e203. CrossRef
Correspondence to letter to the editor 1 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study” Seogsong Jeong, Won Kim, Sang Min Park Clinical and Molecular Hepatology.2025; 31(2): e208. CrossRef
MAFLD or MASLD: Which better represents the prognosis of the steatotic liver population: Letter to the editor on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort st Ying Wang, Shengfeng Wang, Xiude Fan, Jiajun Zhao, Yongfeng Song Clinical and Molecular Hepatology.2025; 31(2): e128. CrossRef
Significant hepatic fat loss after metabolic dysfunction-associated steatotic liver disease: Beware of misclassification as absence of disease Seogsong Jeong Journal of Hepatology.2025; 83(3): e156. CrossRef
Metabolic Dysfunction-Associated Steatotic Liver Disease in the Korean General Population: Epidemiology, Risk Factors, and Non-Invasive Screening Yong Jun Choi, Jooheon Park, Han-Ik Cho, Myung Geun Shin, Eun-Hee Nah Metabolites.2025; 15(5): 299. CrossRef
Protective effects of Ginkgo biloba supplementation on clinical outcomes in metabolic dysfunction-associated steatotic liver disease Tom Ryu, Beom Sun Chung, Jaejun Lee, Ji Won Han, Hyun Yang, Keungmo Yang Phytomedicine.2025; 143: 156889. CrossRef
Proteomic variation underlies the heterogeneous risk of metabolic dysfunction-associated steatotic liver disease for subsequent chronic diseases Jialong Wu, Gonghua Wu, Jiawei Li, Bo Yi, Qingyi Jia, Ke Ju, Qingyang Shi, Zixuan Wang, Xiong Xiao, Bing Guo, Huan Xu, Xing Zhao European Journal of Endocrinology.2025; 192(5): 691. CrossRef
Association between green space and hepatocellular carcinoma risk: a retrospective cohort study of seven South Korean metropolitan areas Dong Hyun Kim, Seulggie Choi, Seogsong Jeong, Jooyoung Chang, Sung Min Kim, Sun Jae Park, Jun Hwan Kim, Joung Sik Son, Gyeongsil Lee, Soo Jung Choi, Yun Hwan Oh, Kyae Hyung Kim, Sang Min Park International Journal of Environmental Health Research.2025; 35(12): 4026. CrossRef
Early portal hypertension in metabolic dysfunction-associated steatotic liver disease: a concise review Iván López-Méndez, Eva Juárez-Hernández, Juan Pablo Soriano-Márquez, Misael Uribe, Graciela Castro-Narro Expert Review of Gastroenterology & Hepatology.2025; 19(7): 755. CrossRef
Identification of potentially effective drugs for metabolic dysfunction-associated steatotic liver disease against liver cirrhosis: In-silico drug repositioning-based retrospective cohort study Chae Won Lee, Eun Seok Kang, Seogsong Jeong, Hyun Wook Han, Samuel O. Antwi PLOS One.2025; 20(6): e0323880. CrossRef
All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study Jeayeon Park, Goh Eun Chung, Su Jong Yu, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Eun Ju Cho JHEP Reports.2025; 7(9): 101477. CrossRef
From mechanisms to management: Early detection and improved treatment of MASLD and its related hepatocellular carcinoma Dingwu Li, Xiang Zhang Hepatology Communications.2025;[Epub] CrossRef
Lean Metabolic Dysfunction-Associated Steatotic Liver Disease and Dementia Risk: A High-Risk Phenotype beyond Body Mass Index Seogsong Jeong Gut and Liver.2026; 20(1): 3. CrossRef
Digestive System Diseases, Genetic Risk, and Incident Dementia: A Prospective Cohort Study Shuai Yuan, Lintao Dan, Yao Zhang, Jing Wu, Jianhui Zhao, Miia Kivipelto, Jie Chen, Jonas F. Ludvigsson, Xue Li, Susanna C. Larsson American Journal of Preventive Medicine.2024; 66(3): 516. CrossRef
Fatty liver index as an independent predictor of all-cause and disease-specific mortality Ruixin Zhang, Shuhao Ren, Hongfei Mi, Meixia Wang, Tingjuan He, Renyan Zhang, Wei Jiang, Chenghao Su European Journal of Gastroenterology & Hepatology.2024; 36(12): 1453. CrossRef
New Insights into the Role of SGLT-2 Inhibitors in the Prevention of Dementia Cheng-Hsien Hung, Li-Yu Lu Neurology International.2024; 16(6): 1717. CrossRef
Risk Stratification for Sarcopenic Obesity in Subjects With Nonalcoholic Fatty Liver Disease Ho Soo Chun, Minjong Lee, Hye Ah Lee, Sejin Lee, Soyeon Kim, Ye Jun Jung, Chaewon Lee, Hyoeun Kim, Han Ah Lee, Hwi Young Kim, Kwon Yoo, Tae Hun Kim, Sang Hoon Ahn, Seung Up Kim Clinical Gastroenterology and Hepatology.2023; 21(9): 2298. CrossRef
The Relationship between Cancer and Dementia: An Updated Review Yung-Shuo Kao, Cheng-Chang Yeh, Yi-Fang Chen Cancers.2023; 15(3): 640. CrossRef
NAFLD does not increase the risk of incident dementia: A prospective study and meta-analysis Hangkai Huang, Zhening Liu, Jiarong Xie, Chengfu Xu Journal of Psychiatric Research.2023; 161: 435. CrossRef
The association between regional adiposity, cognitive function, and dementia-related brain changes: a systematic review Ethel Boccara, Sapir Golan, Michal Schnaider Beeri Frontiers in Medicine.2023;[Epub] CrossRef
Letter regarding “Non-alcoholic fatty liver disease: Definition and subtypes” Seogsong Jeong, Yohwan Lim, Su Kyoung Lee, Hyun Wook Han Clinical and Molecular Hepatology.2023; 29(3): 810. CrossRef
First
Prev
